High–quality iPSC derived lines from patient and control human donors
Commercially available and consented iPSC lines
We have an extensive commercial library iPSCs from a range of patient and healthy donors. The cell lines include those from healthy donors and those with:
- Alzheimer’s Disease
- Parkinson’s Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Frontotemporal Dementia
- Friedreich’s Ataxia
- Huntington’s Disease
- See all
Our axoLinesTM iPSCs are used for axoServicesTM custom lab services, made-to-order axoCellsTM projects and specific licensing arrangements.
The lines are derived from patient and healthy samples. To ensure high-quality cells that more closely mimic in vivo physiology, we extract fibroblasts or PBMCs from consenting donors and reprogram them into iPSCs, guided by our decades of scientific experience.
How axoLinesTM can support your research:
- An extensive library of lines from a wide range of healthy and patient donors
- Diverse library including sibling and familial partners
- 50:50 split of male/female donors to address sex disparities in biopharma research
- Our reputation for quality has led to collaboration with leading research institutes and top ten biopharma
Unaffected donors iPSCs / ‘Control lines’
| Donor | Lines available |
| Unaffected by disease at time of donation | Male, 74, ApoE: E2/E2 |
| Male, 40-50, APOE: E2/E3 | |
| Female, 45, APOE: E3/E3; ATN: 12/13 CAG repeats | |
| Male, 70, ApoE: E3/E3 | |
| Male, 81, ApoE: E3/E3 | |
| Male, 73, ApoE: E2/E3 | |
| Male, 44, FXN: 8 GAA repeats | |
| Male, Newborn, ApoE: E3/E4 | |
| Female, Newborn, ApoE: E3/E4 |
Patient donor iPSCs
| Donor Condition | Lines Available | |
| Amyotrophic Lateral Sclerosis (ALS) | Female, 44, C9orf72: >100 G4C2 (Asymptomatic Carrier) | |
| Female, 61, SOD1: Het. D109Y | ||
| Female, 64, C9orf72: >145 G4C2 | ||
| Male, 62, C9orf72: >145 G4C2 (Asymptomatic Carrier) | ||
| Alzheimer’s Disease | Male, 77, ApoE: E2/E3 | |
| Female, 59, ApoE: E3/E3 | ||
| Female, 79, ApoE: E3/E3 | ||
| Male, 80, ApoE: E3/E3 | ||
| Male, 83, ApoE: E3/E3 | ||
| Female, 52, ApoE: E3/E4 | ||
| Female, 72, ApoE: E3/E4 | ||
| Male, 60, ApoE: E3/E4 | ||
| Male, 70, ApoE: E3/E4 | ||
| Male, 72, ApoE: E3/E4 | ||
| Male, 74, ApoE: E3/E4 | ||
| Male, 77, ApoE: E3/E4 | ||
| Male, 82, ApoE: E3/E4 | ||
| Female, 69, ApoE: E4/E4 | ||
| Female, 76, ApoE: E4/E4 | ||
| FTD | Behavioural variant frontotemporal dementia (bvFTD) | Male, 65, MAPT: Het. c.1920+16C>T |
| Male, 68, MAPT: Het. c.1920+16C>T | ||
| Male, 59, MAPT: Het. c.1920+16C>T | ||
| ALS/FTD | Female, 64, TARDBP: A382T | |
| FTD, Paget’s Disease | Female, 31, Progranulin: R493X | |
| Male, 65, Progranulin: C31FS | ||
| Female, 46, MAPT: Het. c.1920+16C>T (Asymptomatic Carrier) | ||
| Female, 54, MAPT: Het. c.1920+16C>T | ||
| Female, 42, MAPT: Het. c.1920+16C>T | ||
| Male, 35, MAPT: Het. c.1920+16C>T | ||
| Female, 43, VCP: Het. VCP R155C | ||
| Male, 42, VCP: Het. VCP R191Q | ||
| Charcot-Marie-Tooth Disease, Type 4J | Male, 27, FIG4: Het. c.122T>C p.(l41T) exon 2 | |
| Dentatorubral-pallidoluysian atrophy (DRPLA) | Male, 16, ATN1: 13/66 CAG | |
| Male, 51, ATN1: 17/57 CAG | ||
| Female, 45, ATN1: 12/13 CAG (Asymptomatic Carrier) | ||
| Friedreich’s Ataxia | Male, 21, FXN: >75 GAA | |
| Female, Unknown , FXN: >75 GAA (Asymptomatic Carrier) | ||
| Male, 44, FXN: 8 GAA (Asymptomatic Carrier) | ||
| Female, 17, FXN: >75 GAA | ||
| Male, 23, FXN: >66 GAA | ||
| Male, 34, FXN: >75 GAA | ||
| Huntington’s Disease | Female, 40-50, HTT: 18/39 CAG | |
| Female, 51, HTT: 42/17 CAG | ||
| Female, 7, HTT: 127/14 CAG | ||
| Male, 16, HTT: 28/66 CAG | ||
| Male, 64, HTT: 17/38 CAG (Asymptomatic Carrier) | ||
| Mucolipidosis IV (ML4) | Female, 36, MCOLN1: Het. c.785T>C (Asymptomatic Carrier) | |
| Female, 10, MCOLN1: Hom. c.406-2A>G | ||
| Male, 45, MCOLN1: Het. c.406-2A>G | ||
| Male, 7, MCOLN1: Het. c.694A>C p.(T232P); Het. c.785T>C p.(F262S) | ||
| Nasu-Hakola Disease | Female, 41, TREM2: Hom. c.150G>T p.(W50C) | |
| Female, 69, TREM2: Het. c.150G>T p.(W50C) (Asymptomatic Carrier) | ||
| Male, 68, TREM2: Het. c.150G>T p.(W50C) (Asymptomatic Carrier) | ||
| Parkinsonism/Machado-Joseph disease/SCA3 | Male, 50, ATXN3: 14/69 CAG | |
| Female, 53, ATXN3: 26/70 CAG | ||
| Parkinson’s Disease | Female, 48, PINK1: W90Lfsx12 & PARKIN: R275W | |
| Male, 75, Het. PARK1 & PARK2 Variant | ||
| Female, 52, PINK1: Hom. W90Lfsx12 | ||
| Spinal and bulbar muscular atrophy (SBMA) | Male, 66, AR: >47 CAG | |
| Spinocerebellar ataxia | Male, 41, ATXN2: 22/38 CAG | |
| Male, 58, ATXN2: 22/36 CAG | ||
| Female, Unknown , ATXN2: 22/39 CAG | ||
| Female, 22, ATXN3: 14/75 CAG | ||
| Female, 63, CACNA1A: Het. 23 CAG | ||
| Female, 61, ATXN7: 10/39 CAG | ||